Shots:

• The termination is based on the recommendation of the Independent Data Monitoring Committee (IDMC) following its review of P-III TAPPAS trials assessing TRC105 (carotuximab) + Votrient (pazopanib) vs Votrient in 340 patients with advanced or metastatic angiosarcoma
• The P-III TAPPAS trial showed disappointing results and demonstrated no efficacy in patients with advanced or metastatic angiosarcoma
• TRC105 (carotuximab) is an antibody to endoglin- currently being evaluated in P-II AVANTE trial in patients with wet AMD and has received ODD in the US & EU. Tracon also develop DE-122 & TRC253 in partnership with Santen & Janssen respectively

Ref: Tracon | Image: Twitter